Enlivex Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENLV research report →
Range $15 – $15
Price Chart
About the company
Enlivex Therapeutics Ltd. , established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic.
- CEO
- Oren Hershkovitz
- IPO
- 2014
- Employees
- 34
- HQ
- Ness Ziona, TA, IL
Get TickerSpark's AI analysis on ENLV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.73M
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 279.88%
- ROIC
- -0.32%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-332,000+39.1%
- Op Income
- $-15,000,000
- Net Income
- $1.24B+8329.2%
- EPS
- $405.60+3804.1%
- OCF Growth
- +19.9%
- FCF Growth
- +20.0%
- 52W High
- $27.15
- 52W Low
- $0.34
- 50D MA
- $1.35
- 200D MA
- $9.85
- Beta
- 1.41
- RSI (14)
- 13
- Avg Volume
- 376.19K
No earnings-call transcripts are available for ENLV yet.
- Free Float
- 99.5%
- Shares Outstanding
- 16.83M
- Float Shares
- 16.75M
of shares held by institutions
36 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ark Investment Management LLC | 2.38M | ▲ 1.75M |
| Prelude Capital Management, LLC | 321.31K | ▲ 95.57K |
| Bank Of America Corp | 193.15K | ▲ 62.75K |
| Two Sigma Investments, LP | 183.92K | ▲ 37.51K |
| Susquehanna International Group, Llp | 157.65K | ▲ 147.33K |
| Persistent Asset Partners Ltd | 147.88K | ▲ 147.88K |
| Renaissance Technologies LLC | 133.90K | ▲ 5.71K |
| Geode Capital Management, LLC | 129.86K | ▲ 49.30K |
| Jpmorgan Chase & Co | 121.30K | ▼ 4.65K |
| Simplex Trading, LLC | 111.41K | ▲ 108.79K |
| Winton Group Ltd | 99.22K | ▲ 99.22K |
| Goldman Sachs Group Inc | 89.42K | ▼ 12.68K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Hershkovitz Oren | other | 0 |
| Nov 16, 23 | Hershkovitz Oren | other | 150,000 |
| Nov 24, 25 | Hershkovitz Oren | other | 60,000 |
| Mar 18, 26 | Shlosberger Shachar | other | 0 |
| Mar 7, 21 | Shlosberger Shachar | other | 1,452 |
| Dec 12, 21 | Shlosberger Shachar | other | 1,452 |
| Mar 30, 24 | Shlosberger Shachar | other | 5,000 |
| Dec 10, 22 | Shlosberger Shachar | other | 1,452 |
| Nov 24, 25 | Shlosberger Shachar | other | 10,000 |
| Nov 24, 25 | Shlosberger Shachar | other | 7,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENLV coverage
Recent articles, reports, and earnings notes.
No research on ENLV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENLV report →Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Down 59.8% in September
defenseworld.net · Sep 30
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
globenewswire.com · Sep 22
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com · Sep 1
Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)
defenseworld.net · Aug 21
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
globenewswire.com · Jul 30
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
globenewswire.com · Jul 29
Enlivex Announces $400,000,000 Private Placement
globenewswire.com · Jul 28
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
defenseworld.net · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.